Pharsight

1. List of Goprelto drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10933060	GENUS LIFESCIENCES	Pharmaceutical compositions and methods of using the same	Feb, 2037 (14 years from now)
US10973811	GENUS LIFESCIENCES	Pharmaceutical compositions and methods of using the same	Feb, 2037 (14 years from now)
US10987347	GENUS LIFESCIENCES	Pharmaceutical compositions and methods of using the same	Feb, 2037 (14 years from now)
US10894012	GENUS LIFESCIENCES	Pharmaceutical compositions and methods of using the same	Feb, 2037 (14 years from now)
US10857095	GENUS LIFESCIENCES	Pharmaceutical compositions and methods of using the same	Feb, 2037 (14 years from now)
US10231961	GENUS LIFESCIENCES	Pharmaceutical compositions and methods of using the same	Feb, 2037 (14 years from now)
US11040032	GENUS LIFESCIENCES	Pharmaceutical compositions and methods of using the same	Feb, 2037 (14 years from now)
US10016407	GENUS LIFESCIENCES	Pharmaceutical compositions and methods of using the same	Feb, 2037 (14 years from now)
US9867815	GENUS LIFESCIENCES	Pharmaceutical compositions and methods of using the same	Feb, 2037 (14 years from now)
US10413505	GENUS LIFESCIENCES	Pharmaceutical compositions and methods of using the same	Feb, 2037 (14 years from now)
US10420760	GENUS LIFESCIENCES	Pharmaceutical compositions and methods of using the same	Feb, 2037 (14 years from now)
US10149843	GENUS LIFESCIENCES	Pharmaceutical compositions and methods of using the same	Feb, 2037 (14 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Dec 14, 2022

Drugs and Companies using COCAINE HYDROCHLORIDE ingredient

NCE-1 date: December, 2021

Market Authorisation Date: 14 December, 2017

Treatment: Method for the induction of local anesthesia of the mucous membranes; Method of administering a local anesthetic to the mucous membranes in patients with renal impairment; Method of administering a local anesthetic to the mucous membranes in patients with hepatic impairment; Method of administering a local anesthetic prior to performing a diagnostic or surgical procedure on a subject with hepatic or renal impairment; Method of administering a local anesthetic to the mucous membranes in geriatric patients; Method of administering a local anesthetic to the mucous membranes; Method for the induction of local anesthesia prior to performing a procedure on, through, or adjacent to the mucous membranes

Dosage: SOLUTION;NASAL

Strength	Dosage	Availability
4%	SOLUTION;NASAL	Prescription

2. List of Levolet drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10231931	GENUS LIFESCIENCES	Thyroid hormone oral dosage forms and methods of using the same	Mar, 2038 (15 years from now)
US10406108	GENUS LIFESCIENCES	Thyroid hormone oral dosage forms and methods of using the same	Mar, 2038 (15 years from now)

Drugs and Companies using LEVOTHYROXINE SODIUM ingredient

Market Authorisation Date: 06 June, 2003

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET;ORAL	Prescription
0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET;ORAL	Prescription
0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET;ORAL	Prescription
0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET;ORAL	Prescription
0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET;ORAL	Prescription
0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET;ORAL	Prescription
0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET;ORAL	Prescription
0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET;ORAL	Prescription
0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET;ORAL	Prescription
0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET;ORAL	Prescription
0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET;ORAL	Prescription
0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET;ORAL	Prescription

3. List of Yosprala drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9364439	GENUS LIFESCIENCES	Pharmaceutical compositions for the coordinated delivery of NSAIDs	May, 2022 (7 months ago)
US6926907	GENUS LIFESCIENCES	Pharmaceutical compositions for the coordinated delivery of NSAIDs	Feb, 2023 (a month from now)
US8206741	GENUS LIFESCIENCES	Pharmaceutical compositions for the coordinated delivery of NSAIDs	Feb, 2023 (a month from now)
US9987231	GENUS LIFESCIENCES	Compositions and methods for delivery of omeprazole plus acetylsalicylic acid	Jan, 2033 (9 years from now)
US9539214	GENUS LIFESCIENCES	Compositions and methods for delivery of omeprazole plus acetylsalicylic acid	Mar, 2033 (10 years from now)

Drugs and Companies using ASPIRIN; OMEPRAZOLE ingredient

Market Authorisation Date: 14 September, 2016

Treatment: Treatment or secondary prevention of cardiovascular disease, cardiovascular events, or cerebrovascular events and risk-reduction of aspirin-associated gastric ulcers; For secondary prevention of cardiovascular and cerebrovascular events in patients at risk of developing aspirin-associated gastric ulcers

Dosage: TABLET, DELAYED RELEASE;ORAL